Thermo Fisher Expands Real-World Data Capabilities with HealthVerity Deal
Event summary
- Thermo Fisher’s PPD clinical research business has partnered with HealthVerity to access its TaXOnomy® claims dataset, covering 270M de-identified patient lives in the U.S.
- The deal provides enterprise-level access to over 70 curated data sources, including electronic medical records and lab results.
- Thermo Fisher aims to enhance trial feasibility, recruitment, and real-world evidence generation with AI-driven analytics.
- The collaboration strengthens PPD’s CorEvitas Clinical Registries and Evidera solutions for faster analytics and expanded registry-linked claims capabilities.
The big picture
This collaboration underscores the growing importance of real-world data in clinical development, as biopharma companies seek more precise and efficient trial methodologies. With annual revenue exceeding $40B, Thermo Fisher is positioning itself as a leader in AI-driven clinical research services, aiming to reduce startup timelines and enhance evidence generation for sponsors.
What we're watching
- Data Integration
- How Thermo Fisher will leverage HealthVerity’s dataset to improve clinical trial design and execution efficiency.
- Competitive Edge
- Whether the expanded real-world data capabilities will differentiate PPD in the crowded clinical research market.
- Regulatory Compliance
- The pace at which Thermo Fisher can maintain rigorous privacy protections while scaling access to sensitive healthcare data.